Literature DB >> 9489597

Exogenous L-arginine does not affect angiotensin II-induced renal vasoconstriction in man.

M Wolzt1, A Ugurluoglu, L Schmetterer, G Dorner, G Zanaschka, C Mensik, H G Eichler.   

Abstract

AIMS: It has been suggested that provision of the substrate of nitric oxide (NO) synthesis, L-arginine, might influence the effects of renal vasoconstrictors. We have therefore studied the effects of pretreatment or concomitant administration of L-arginine on angiotensin II (ANG II)-increased renovascular resistance.
METHODS: The study was conducted in a double-blind, randomized, cross-over design. Eight healthy subjects were assigned to placebo or a continuous intravenous coinfusion of ANG II (5.0 ng kg[-1] min[-1], infusion period 75 min) with L-arginine (17 mg kg[-1] min[-1], infusion period 30 min). Nine further subjects received a continuous infusion of ANG II with or without pretreatment of L-arginine. Changes in renal plasma flow (RPF) were estimated by the steady state clearance of PAH.
RESULTS: L-arginine alone increased RPF to 110 +/- 10% over baseline (P < 0.003). The ANG II-induced decrease in RPF was not affected by pretreatment or coinfusion of L-arginine.
CONCLUSIONS: Our results demonstrate that a counterregulatory response of the renal vasculature to high levels of ANG II does not depend on exogenous L-arginine. In healthy subjects, this lack of functional antagonism at the renal vasculature is therefore not a result of NO substrate availability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489597      PMCID: PMC1873991          DOI: 10.1046/j.1365-2125.1998.00634.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli.

Authors:  K M Denton; P A Fennessy; D Alcorn; W P Anderson
Journal:  Am J Physiol       Date:  1992-03

2.  L-arginine-induced hypotension.

Authors: 
Journal:  Lancet       Date:  1990-10-20       Impact factor: 79.321

3.  Simplified measurement of p-aminohippurate and other arylamines in plasma and urine.

Authors:  W H Waugh; P T Beall
Journal:  Kidney Int       Date:  1974-06       Impact factor: 10.612

4.  Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries.

Authors:  V Richard; F C Tanner; M Tschudi; T F Lüscher
Journal:  Am J Physiol       Date:  1990-11

5.  Basal nitric oxide synthesis in essential hypertension.

Authors:  P Forte; M Copland; L M Smith; E Milne; J Sutherland; N Benjamin
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

6.  Microvascular reactivity of in vitro blood perfused juxtamedullary nephrons from rats.

Authors:  D Casellas; P K Carmines; L G Navar
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

7.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

8.  NG-hydroxy-L-arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat.

Authors:  C E Walder; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

9.  The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.

Authors:  L F Prescott; S Freestone; J A McAuslane
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

10.  Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure.

Authors:  M A Munger; M Chance; R Nair; A W Prescott; A R Nara; M S Simonson; J A Green; E L Posvar
Journal:  J Clin Pharmacol       Date:  1992-01       Impact factor: 3.126

View more
  1 in total

Review 1.  The Effects of L-Arginine in Hypertensive Patients: A Literature Review.

Authors:  Abdulkarim W Abukhodair; Walid Abukhudair; Mohammed S Alqarni
Journal:  Cureus       Date:  2021-12-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.